Novo Nordisk A/S (BVMF:N1VO34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 997.63B -38.4% |
| Revenue (ttm) | 263.81B +8.1% |
| Net Income | 98.15B +16.6% |
| EPS | 22.06 +16.8% |
| Shares Out | n/a |
| PE Ratio | 10.16 |
| Forward PE | 14.18 |
| Dividend | 0.77 (2.75%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 8,204 |
| Average Volume | 29,114 |
| Open | 28.27 |
| Previous Close | 27.99 |
| Day's Range | 28.05 - 28.30 |
| 52-Week Range | 22.90 - 57.25 |
| Beta | 0.35 |
| RSI | 56.09 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Moderately bullish activity in Novo Nordisk with shares up 0.6%
Moderately bullish activity in Novo Nordisk (NVO), with shares up 26c, or 0.6%, near $44.55. Options volume nearly triple the daily average with 142k contracts traded and calls leading puts…
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party
There is a need for more weight loss drug options, including oral pills. Viking Therapeutics is working on a promising one, though tolerability might be an issue.
PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’
Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed that President Donald Trump is set to announce…
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now
Shares of Pfizer, Novo Nordisk, and PDD Holdings trade at incredibly low valuations right now. These stocks are trading at significant discounts relative to their future earnings.
US Supreme Court rebuffs pharma challenge to Biden-era drug price
The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 A...
Novo Nordisk Prepares Wegovy Launch Amidst Growing Weight Loss Drug Competition
Novo Nordisk Prepares Wegovy Launch Amidst Growing Weight Loss Drug Competition
Novo Nordisk Eyes Global Push for Wegovy Pill
Novo Nordisk Eyes Global Push for Wegovy Pill
Novo Nordisk's next obesity battlefront: Winning beyond America
Novo Nordisk sees a "major opportunity" outside of the U.S. and says that telehealth partners could help grow the global market for weight loss drugs. The battle for dominance over the lucrative marke...
As millions flock to GLP-1s, doctors warn of a rise in frailty caused by rapid muscle wasting
Losing muscle, as well as fat, is an unexpected downside of the popular drugs that isn't broadly discussed or immediately apparent.
Mixed options sentiment in Novo Nordisk with shares down 2.61%
Mixed options sentiment in Novo Nordisk (NVO), with shares down $1.20 near $44.60. Options volume relatively light with 26k contracts traded and calls leading puts for a put/call ratio of…
Buy, Sell, or Hold Novo Nordisk at $46?
The bulk of Novo Nordisk's sales come from weight-loss and diabetes treatments. The biotech faces competition from companies like Eli Lilly and Pfizer, among others.
Best Healthcare Stocks to Buy in 2026
Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
Novo Nordisk (NVO) Expected to See Significant Upside Potential
Novo Nordisk (NVO) Expected to See Significant Upside Potential
Is Novo Nordisk's Rebound for Real--or Just a Head Fake?
Novo Nordisk recently posted strong quarterly results. Newer launches are boosting sales.
Novo Nordisk A/S Q1 Earnings Call Highlights
Novo Nordisk A/S NYSE: NVO said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipelin...
Novo Nordisk A/S Q1 Earnings Call Highlights
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy...
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end o...
Mixed options sentiment in Novo Nordisk with shares up 1.26%
Mixed options sentiment in Novo Nordisk (NVO), with shares up 58c, or 1.26%, near $46.98. Options volume relatively light with 44k contracts traded and calls leading puts for a put/call…
NVO: Novo Nordisk Highlights Wegovy's Impact on Weight Loss Among Women
NVO: Novo Nordisk Highlights Wegovy's Impact on Weight Loss Among Women
Novo Nordisk price target raised to DKK 290 from DKK 275 at Citi
Citi raised the firm’s price target on Novo Nordisk (NVO) to DKK 290 from DKK 275 and keeps a Neutral rating on the shares.
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
Novo Nordisk updates on Wegovy results in women across menopause stages
The company states: “Novo Nordisk (NVO) today announced data demonstrating that Wegovy (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity ac...